SG11201900808SA - Compositions and methods of replication deficient adenoviral vectors for vaccine applications - Google Patents

Compositions and methods of replication deficient adenoviral vectors for vaccine applications

Info

Publication number
SG11201900808SA
SG11201900808SA SG11201900808SA SG11201900808SA SG11201900808SA SG 11201900808S A SG11201900808S A SG 11201900808SA SG 11201900808S A SG11201900808S A SG 11201900808SA SG 11201900808S A SG11201900808S A SG 11201900808SA SG 11201900808S A SG11201900808S A SG 11201900808SA
Authority
SG
Singapore
Prior art keywords
international
methods
pennsylvania
rule
philadelphia
Prior art date
Application number
SG11201900808SA
Inventor
Hildegund C J Ertl
xiang yang Zhou
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Publication of SG11201900808SA publication Critical patent/SG11201900808SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIP0 I PCT onion °nolo oliolomu ioo Mo Imo ois (10) International Publication Number WO 2018/026547 Al (51) International Patent Classification: A61K 47/48 (2006.01) CO7K 14/005 (2006.01) A61K 48/00 (2006.01) (21) International Application Number: PCT/US2017/043315 (22) International Filing Date: 21 July 2017 (21.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/369,288 01 August 2016 (01.08.2016) US (71) Applicant: THE WISTAR INSTITUTE OF ANATO- MY AND BIOLOGY [US/US]; 3601 SPRUCE STREET, PHILADELPHIA, Pennsylvania 19104 (US). (72) Inventors: ERTL, Hildegund C.J.; c/o THE WIS- TAR INSTITUTE OF ANATOMY AND BIOLOGY, 3601 SPRUCE STREET, PHILADELPHIA, Pennsylvania 19104 (US). ZHOU, Xiang Yang; 230 Tudor Drive, North Wales, Pennsylvania 19454 (US). (74) Agent: DOYLE, Kathryn et al.; Saul Ewing, LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) N O cc O C (54) Title: COMPOSITIONS AND METHODS OF REPLICATION DEFICIENT ADENOVIRAL VECTORS FOR VACCINE AP- PLICATIONS (57) : The invention includes compositions and methods of generating a chimpanzee-derived adenovirus AdC6 or AdC7 vector vaccine comprising a deletion of El, a deletion of E3 ORF3, ORF4, ORF5, ORF6, and ORF7 and a sequence encoding HIV protein gp140, gp160 or Gag, methods of treating and/or preventing or immunizing against HIV and methods of inducing an effector T cell, memory T cell and B cell immune response in a mammal administered the composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a mammal as well as a protein expression system.
SG11201900808SA 2016-08-01 2017-07-21 Compositions and methods of replication deficient adenoviral vectors for vaccine applications SG11201900808SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662369288P 2016-08-01 2016-08-01
PCT/US2017/043315 WO2018026547A1 (en) 2016-08-01 2017-07-21 Compositions and methods of replication deficient adenoviral vectors for vaccine applications

Publications (1)

Publication Number Publication Date
SG11201900808SA true SG11201900808SA (en) 2019-02-27

Family

ID=61073904

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900808SA SG11201900808SA (en) 2016-08-01 2017-07-21 Compositions and methods of replication deficient adenoviral vectors for vaccine applications

Country Status (7)

Country Link
US (1) US10953108B2 (en)
EP (1) EP3490610A4 (en)
CN (1) CN109804075A (en)
AU (1) AU2017305176B2 (en)
SG (1) SG11201900808SA (en)
WO (1) WO2018026547A1 (en)
ZA (1) ZA201900941B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
EP3576759A4 (en) 2017-01-31 2020-11-11 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018170147A1 (en) 2017-03-14 2018-09-20 The Regents Of The University Of California Genome-wide identification of immune evasion functions in a virus
WO2020072371A1 (en) * 2018-10-01 2020-04-09 The Wistar Institute Melanoma canine vaccine compositions and methods of use thereof
WO2020214203A1 (en) * 2019-04-17 2020-10-22 The Wistar Institute Replication deficient adenoviral vectors for hiv vaccine applications
CN113088530A (en) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 Expression vector based on chimpanzee ChAd63 adenovirus and construction method thereof
JP2023510544A (en) 2020-01-09 2023-03-14 ビリオン セラピューティクス，リミティド ライアビリティ カンパニー Adenoviral vector encoding hepatitis B virus antigen fused with herpesvirus glycoprotein D and method of use thereof
CN112156178B (en) * 2020-11-26 2021-03-16 怡道生物科技(苏州)有限公司 Noro virus vaccine based on chimpanzee adenovirus vector, preparation method and application thereof
CN112625112B (en) * 2020-12-16 2022-03-29 熊猫乳品集团股份有限公司 Bioactive polypeptide PAAPAQLPKKI, and preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
AU2002332736A1 (en) 2001-08-30 2003-03-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of New adenovirus type 7 vectors
CA2466431C (en) * 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1336619A3 (en) 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
US7387614B2 (en) 2003-08-26 2008-06-17 University Of Maryland, Baltimore Drug delivery to the inner ear and methods of using same
BRPI0608798A2 (en) 2005-05-12 2011-03-15 Glaxo Group Ltd adenovirus vector, immunogenic composition, use of an adenovirus vector, method for preparing a vector, use of a virus vector and a pharmaceutically acceptable carrier or adjuvant, and fusion protein
CA2634377A1 (en) 2005-12-21 2007-06-28 Glaxo Group Limited Method of eliciting immune response
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
WO2013173702A2 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
US9624510B2 (en) * 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
CN103923943B (en) * 2013-08-19 2019-01-22 中国科学院上海巴斯德研究所 A kind of expression vector and its construction method based on adenovirus AdC7

Also Published As

Publication number Publication date
US20190167813A1 (en) 2019-06-06
EP3490610A1 (en) 2019-06-05
ZA201900941B (en) 2021-06-30
AU2017305176B2 (en) 2021-05-27
EP3490610A4 (en) 2020-05-20
CN109804075A (en) 2019-05-24
AU2017305176A1 (en) 2019-02-28
US10953108B2 (en) 2021-03-23
WO2018026547A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
SG11201900808SA (en) Compositions and methods of replication deficient adenoviral vectors for vaccine applications
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201909870SA (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
SG11201903514VA (en) Novel cd47 monoclonal antibodies and uses thereof
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201811178UA (en) Adenoviral vector
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201804729RA (en) Methods and compositions for treating a serpinc1-associated disorder
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11201408174UA (en) Antibody formulation
SG11201803906PA (en) Control of cellular redox levels
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201809100QA (en) Use of gram negative species to treat atopic dermatitis
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201805001UA (en) Method of treating influenza a
SG11201810549TA (en) Hiv vaccine formulation